MISSISSAUGA, Ontario, June 1 -- General Electric issued the following news release:
GE Healthcare today announced that the OmnyxTM Integrated Digital Pathology (IDP) solution with the new VL120 high volume scanner has obtained a Health Canada Class II Medical Device License for primary diagnostic use. The OmnyxTM IDP with VL4 scanner was licensed in 2013 and has been developed by Omnyx, LLC, a joint venture of GE Healthcare and UPMC.
The number of newly diagnosed cancer cases in Canada is increasing. About 2 in 5 Canadians will develop cancer in their lifetimes.* By bringing pathology into digital workflow, pathologists and their colleagues can collaborate more efficiently to reach timely diagnosis and potentially help improve outcomes for cancer patients in Canada.
Mamar Gelaye, CEO of Omnyx, said: "Pathologists play a significant role in the diagnosis and treatment across many care pathways, particularly cancer. Traditionally, pathologists use a microscope to examine tissue on glass slides. This often requires that glass slides be transported to remote pathologists, creating delays in diagnosis and risk of slides being damaged or lost. It can make getting second opinions and access to subspecialists difficult.
"The OmnyxTM IDP solution provides a powerful digital platform to pathologists to transform how they deliver services. With the ability for pathologists to collaborate across locations without the time needed to transport the glass slides, patients can have greater access to subspecialists regardless of where they live and receive care."
Designed in cooperation with histologists and pathologists, the OmnyxTM VL120 scanner's intuitive workflow enables histology labs to manage high case volumes with continuous loading capability, adapting to the labs' slide production schedule. With this addition to the platform, the solution can enable more patients to have access to collaborative and subspecialty pathology services.
The University Health Network (UHN) Laboratory Medicine Program, one of the largest diagnostic labs in Canada, was a clinical test site for the OmnyxTM IDP and VL120. Dr. Sylvia Asa, Medical Director, Laboratory Medicine Program, UHN said: "We are committed to being a leader in the world of pathology with a vision to improve the way we deliver patient care. This means investing in technology and infrastructure for improved workflow. The collaboration with Omnyx to validate the OmnyxTM VL120 was important to demonstrate that digital platforms can be used for primary diagnosis at high volumes."
"The distribution of population across vast areas of Canada creates significant challenges for our healthcare system in providing access to pathology services," noted Mike Clarke, General Manager of GE Healthcare Canada IT. "GE Healthcare's investment in Omnyx supports our commitment to cancer with technology that allows pathologists to share their expertise more efficiently with peers, clinicians, and patients across the regions they serve."
Omnyx is a trademark of Omnyx, LLC.
* Canadian Cancer Society. 2014. http://www.cancer.ca/en/cancer-information/cancer-101/canadian-cancer-statistics-publication/?region=on#ixzz30qiV3faq. Accessed May 2014.
TNS 30FurigayJof-140603-4754954 30FurigayJof